Adamas Pharmaceuticals (NASDAQ:ADMS)‘s stock had its “buy” rating reaffirmed by research analysts at Mizuho in a note issued to investors on Friday. They presently have a $49.00 target price on the specialty pharmaceutical company’s stock. Mizuho’s price target indicates a potential upside of 77.09% from the company’s previous close.
The analysts wrote, “We believe Adamas is building a solid case for the importance of Gocovri within the Parkinson’s treatment paradigm, thereby increasing the company’s attractiveness as a takeout candidate longer-term. We reiterate our Buy rating and $49 PT.””
Other analysts have also issued reports about the company. Needham & Company LLC set a $40.00 price objective on Adamas Pharmaceuticals and gave the stock a “buy” rating in a research report on Sunday, February 25th. Noble Financial reiterated a “buy” rating on shares of Adamas Pharmaceuticals in a research report on Friday, February 23rd. BidaskClub upgraded Adamas Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday, January 25th. Zacks Investment Research upgraded Adamas Pharmaceuticals from a “hold” rating to a “buy” rating and set a $40.00 price objective for the company in a research report on Wednesday, January 3rd. Finally, Bank of America initiated coverage on Adamas Pharmaceuticals in a research report on Tuesday, March 27th. They issued a “buy” rating and a $39.00 price objective for the company. Two equities research analysts have rated the stock with a sell rating and twelve have assigned a buy rating to the stock. Adamas Pharmaceuticals has a consensus rating of “Buy” and a consensus target price of $43.00.
Shares of ADMS stock opened at $27.67 on Friday. The company has a debt-to-equity ratio of 1.55, a current ratio of 10.79 and a quick ratio of 10.69. The stock has a market capitalization of $670.45, a P/E ratio of -6.97 and a beta of 1.59. Adamas Pharmaceuticals has a 12 month low of $13.50 and a 12 month high of $44.00.
Adamas Pharmaceuticals (NASDAQ:ADMS) last announced its quarterly earnings data on Thursday, February 22nd. The specialty pharmaceutical company reported ($1.27) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.18) by ($0.09). The company had revenue of $0.57 million during the quarter, compared to analysts’ expectations of $0.84 million. The firm’s revenue for the quarter was up 1435.1% on a year-over-year basis. During the same period last year, the firm posted ($0.68) EPS. equities analysts anticipate that Adamas Pharmaceuticals will post -5.87 earnings per share for the current fiscal year.
In other Adamas Pharmaceuticals news, insider Rajiv Patni sold 1,252 shares of the firm’s stock in a transaction dated Wednesday, March 21st. The stock was sold at an average price of $25.94, for a total transaction of $32,476.88. Following the transaction, the insider now owns 21,515 shares in the company, valued at $558,099.10. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, CEO Gregory T. Went sold 4,541 shares of the firm’s stock in a transaction dated Wednesday, March 21st. The stock was sold at an average price of $25.75, for a total value of $116,930.75. Following the transaction, the chief executive officer now owns 182,610 shares in the company, valued at approximately $4,702,207.50. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 6,360 shares of company stock worth $164,138. Company insiders own 29.00% of the company’s stock.
A number of institutional investors and hedge funds have recently modified their holdings of ADMS. SG Americas Securities LLC bought a new position in Adamas Pharmaceuticals during the third quarter worth about $110,000. JPMorgan Chase & Co. lifted its holdings in shares of Adamas Pharmaceuticals by 13,028.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 136,273 shares of the specialty pharmaceutical company’s stock valued at $2,839,000 after purchasing an additional 135,235 shares in the last quarter. Schwab Charles Investment Management Inc. lifted its holdings in shares of Adamas Pharmaceuticals by 11.7% during the 4th quarter. Schwab Charles Investment Management Inc. now owns 30,690 shares of the specialty pharmaceutical company’s stock valued at $1,041,000 after purchasing an additional 3,218 shares in the last quarter. Hartwell J M Limited Partnership lifted its holdings in shares of Adamas Pharmaceuticals by 65.0% during the 4th quarter. Hartwell J M Limited Partnership now owns 16,500 shares of the specialty pharmaceutical company’s stock valued at $559,000 after purchasing an additional 6,500 shares in the last quarter. Finally, American Century Companies Inc. bought a new position in shares of Adamas Pharmaceuticals during the 4th quarter valued at about $2,110,000. Hedge funds and other institutional investors own 77.33% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This report was originally reported by The Lincolnian Online and is owned by of The Lincolnian Online. If you are reading this report on another website, it was stolen and reposted in violation of U.S. & international copyright and trademark legislation. The correct version of this report can be accessed at https://www.thelincolnianonline.com/2018/04/20/adamas-pharmaceuticals-adms-given-buy-rating-at-mizuho.html.
Adamas Pharmaceuticals Company Profile
Adamas Pharmaceuticals, Inc discovers, develops, and sells therapies for chronic neurologic disorders. The company's approved/commercial product is GOCOVRI, an amantadine therapy for the treatment of levodopa-induced dyskinesia in patients with Parkinson's disease. Its partnered approved/commercial products include Namzaric (memantine hydrochloride extended-release and donepezil hydrochloride) capsules; and Namenda XR (memantine hydrochloride) extended release capsules for the treatment of moderate to severe Alzheimer's disease.
Receive News & Ratings for Adamas Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.